Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EZH2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Wild-Type Enzyme | EZH2 WT Recombinant Protein (Full-length / Catalytic SET Domain) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW. HEK293 Expressed. |
View EZH2 Products |
| Oncogenic Mutants | EZH2 Mutant Recombinant Proteins (Y641F, A677G, A687V, Y641N) Clinically relevant gain-of-function lymphoma mutations. Sequence Verified. >95% Purity. Endotoxin Controlled. |
View EZH2 Products |
| PRC2 Complex | EZH2-EED-SUZ12 Multimeric Complex Reconstituted functional complex for methyltransferase assays. HEK293 Expressed. |
View EZH2 Products |
| Gene Delivery | EZH2 Promise-ORF / Lentivirus (WT & Mutant) Full-length ORF for stable cell line construction. Sequence Verified. |
View EZH2 Products |
| Benchmark Tool | Anti-EZH2 Recombinant Antibody Sequence Verified, ChIP-grade suitable. For pharmacodynamic detection and Western / IHC. |
View EZH2 Products |
| Validator | EZH2 siRNA Set Sequence Verified. For knockdown verification and target specificity confirmation. |
View EZH2 Products |
| PRC2 Partner A | EED (Embryonic Ectoderm Development) Allosteric PRC2 partner essential for EZH2 catalytic activation. |
View EED Products |
| PRC2 Partner B | SUZ12 (Suppressor of Zeste 12) Structural scaffolding subunit for functional PRC2 complex reconstitution. |
View SUZ12 Products |
| Paralog Selectivity | EZH1 Recombinant Protein Compensatory paralog for EZH1/EZH2 dual-inhibition selectivity counter-screening. |
View EZH1 Products |
Critical Assay Challenges & Technical Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs WT Selectivity Screening (Y641F, A677G, A687V) | Matched Pair WT and Mutant Proteins (>95% purity, same batch production) for side-by-side IC50 determination. Endotoxin <1 EU/µg. |
| PRC2 Complex Assembly & Functional Activity | High-purity EED and SUZ12 available for heterotrimeric complex reconstitution. Also ready-to-use EZH2-EED-SUZ12 multimeric complex. |
| EZH1 / EZH2 Paralog Selectivity | High-purity EZH1 ortholog (>95%) for strict counter-screening in dual-inhibitor programs. |
| Epitope Mapping for Allosteric Inhibitors | Full-length and domain-truncated variants (SET domain, CXC domain) available. |
| Acquired Resistance Mutations | Comprehensive panel of clinically relevant mutants (Y641, A677, A687) with theoretical MW verified. |
| Lack of Pharmacodynamic Controls | Clinical Benchmark Antibodies included for precise assay calibration (Western, IHC, ChIP). |
| False Positives / Off-target Effects | Validated EZH2 siRNA Set and Negative Control Mutants for target engagement confirmation. |
Live EZH2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EZH2 therapeutics is intensifying, with major players shifting focus from first-generation SAM-competitive inhibitors to mutant-selective agents, PROTAC degraders, and dual EZH1/2 inhibitors. As Tazemetostat (Epizyme/Ipsen) establishes clinical proof-of-concept in epithelioid sarcoma and follicular lymphoma, the next wave of R&D targets acquired resistance mutations, solid tumor indications through combination strategies (e.g., immune checkpoint inhibitors, AR inhibitors), and synthetic lethality approaches. The market is expected to shift from monotherapy in hematological malignancies to combination therapy in solid tumors, driving demand for high-purity wild-type and mutant EZH2 proteins, PRC2 complex reagents, and validated antibodies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Ipsen (Tazemetostat), Pfizer (PF-06821497), Daiichi Sankyo (Valemetostat) | Follicular Lymphoma, Epithelioid Sarcoma, T-cell Lymphoma | Enzyme Activity Assay (Need High-Purity WT & Mutant Proteins) |
| PROTAC / Degrader | Arvinas, Dialectic Therapeutics; Preclinical Academic Groups | Prostate Cancer, Solid Tumors, Resistance | Degradation Assay (Need High-specificity Antibodies, siRNA for validation) |
| Dual Inhibitor (EZH1/2) | Daiichi Sankyo | T-cell Lymphoma | Selectivity Assay (Need both EZH1 and EZH2 recombinant proteins) |
| Combination Therapy | Roche, Novartis | Immunotherapy-resistant Cancers | PD-L1/EZH2 Dual Target Assays (Need co-expression systems) |
Key Functional Domains & Mutations (Fact-Based Summary)
EZH2 (UniProt Q15910) contains two key functional domains: the CXC domain and the SET domain (catalytic methyltransferase domain). Clinically relevant mutations include gain-of-function hotspots (Y641, A677, A687) commonly found in lymphoma, as well as loss-of-function mutations in the WVS motif (e.g., rs193921148, rs1808822115) that decrease histone methyltransferase activity. TarMart provides recombinant proteins covering both wild-type and all major mutant variants for comprehensive drug discovery screening.